ABVC BioPharma Amends 8-K for Financial Statement Inclusion
Ticker: ABVC · Form: 8-K/A · Filed: Jan 26, 2024 · CIK: 1173313
| Field | Detail |
|---|---|
| Company | Abvc Biopharma, Inc. (ABVC) |
| Form Type | 8-K/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: amendment, financial-statements, disclosure, corporate-governance
TL;DR
**ABVC BioPharma just fixed its 8-K, adding missing financials for better transparency.**
AI Summary
ABVC BioPharma, Inc. filed an 8-K/A on January 26, 2024, to amend its previous 8-K filing from November 16, 2023. This amendment, labeled "Amendment No. 1," primarily updates the filing to include financial statements and exhibits that were likely omitted or needed correction in the original report. This matters to investors because accurate and complete financial disclosures are crucial for evaluating the company's health and making informed investment decisions, ensuring transparency regarding its operations and financial position.
Why It Matters
This amendment ensures investors have access to complete financial information, which is essential for assessing ABVC BioPharma's current financial health and future prospects.
Risk Assessment
Risk Level: low — This filing is an amendment to correct or add information, which generally reduces risk by improving transparency rather than introducing new risks.
Analyst Insight
A smart investor would review the newly included financial statements and exhibits to understand the full financial picture of ABVC BioPharma, Inc. that was previously incomplete, using this information to re-evaluate their investment thesis.
Key Players & Entities
- ABVC BIOPHARMA, INC. (company) — the registrant filing the 8-K/A
- Nevada (company) — state of incorporation for ABVC BioPharma, Inc.
- 001-40700 (company) — Commission File Number for ABVC BioPharma, Inc.
- 26-0014658 (company) — IRS Employer Identification No. for ABVC BioPharma, Inc.
- 44370 Old Warm Springs Blvd. Fremont, CA 94538 (company) — principal executive offices address for ABVC BioPharma, Inc.
- 510-668-0881 (company) — telephone number for ABVC BioPharma, Inc.
FAQ
What is the purpose of this 8-K/A filing by ABVC BioPharma, Inc.?
The purpose of this 8-K/A filing, labeled "AMENDMENT NO. 1 TO FORM 8-K," is to amend a previous Form 8-K, specifically to include "Financial Statements and Exhibits" as indicated in the 'ITEM INFORMATION' section.
What was the original date of the event reported in the initial 8-K that this amendment refers to?
The original event reported in the initial 8-K occurred on November 16, 2023, as stated in the 'Date of Report (Date of earliest event reported): January 25, 2024 (November 16, 2023)' section.
When was this 8-K/A amendment filed with the SEC?
This 8-K/A amendment was filed with the SEC on January 26, 2024, as indicated by 'FILED AS OF DATE: 20240126'.
What is ABVC BioPharma, Inc.'s Central Index Key (CIK) and SEC File Number?
ABVC BioPharma, Inc.'s Central Index Key (CIK) is 0001173313, and its SEC File Number is 001-40700, as detailed in the 'FILER: COMPANY DATA' section.
What is the primary business classification of ABVC BioPharma, Inc. according to its Standard Industrial Classification (SIC)?
ABVC BioPharma, Inc.'s Standard Industrial Classification (SIC) is 'PHARMACEUTICAL PREPARATIONS [2834]', as listed under 'FILER: COMPANY DATA'.
Filing Stats: 657 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2024-01-25 20:04:16
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar
Filing Documents
- ea192147-8ka1_abvcbio.htm (8-K/A) — 28KB
- ea192147ex23-1_abvcbio.htm (EX-23.1) — 2KB
- ea192147ex99-1_abvcbio.htm (EX-99.1) — 58KB
- ea192147ex99-2_abvcbio.htm (EX-99.2) — 90KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-24-006637.txt ( ) — 378KB
- abvc-20231116.xsd (EX-101.SCH) — 3KB
- abvc-20231116_lab.xml (EX-101.LAB) — 33KB
- abvc-20231116_pre.xml (EX-101.PRE) — 22KB
- ea192147-8ka1_abvcbio_htm.xml (XML) — 4KB
01 Financial Statement and Exhibits
Item 9.01 Financial Statement and Exhibits (a) Financial Statements of Business Acquired The audited financial statements of AIBL for the period from January 10, 2023 until September 30, 2023 are attached hereto as Exhibit 99.1. (b) Pro Forma Financial Information. The unaudited pro forma condensed combined balance sheet of the Company and AIBL as of September 30, 2023, the unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2023, and the notes related thereto, reflecting the transaction ("Transaction"), are attached hereto as Exhibit 99.2 and incorporated herein by reference. (d) Exhibits Exhibit No. Description 23.1 Consent of WWC, P.C. 99.1 Audited financial statements of AIBL for the period from January 10, 2023 until September 30, 2023. 99.2 Unaudited pro forma condensed combined statement of operations of the Company and AIBL as of and for the nine months ended September 30, 2023. 104 Cover Page Interactive Data File, formatted in Inline XBRL 2 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABVC BioPharma, Inc. January 25, 2024 By: /s/ Uttam Patil Uttam Patil Chief Executive Officer 3